Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
about
Kinetic and Structural Studies of Phosphodiesterase-8A and Implication on the Inhibitor Selectivity † ‡Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatmentNew insights into the pharmacology of the bladderErectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.The role of phosphodiesterases in bladder pathophysiology.Refolding and kinetic characterization of the phosphodiesterase-8A catalytic domain.
P2860
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
@en
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
@nl
type
label
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
@en
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
@nl
prefLabel
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
@en
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
@nl
P2860
P356
P1476
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
@en
P2093
Barry J Gales
Mark A Gales
P2860
P304
P356
10.1345/APH.1K422
P407
P577
2007-12-19T00:00:00Z